Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
77.73
+0.72 (+0.93%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
48
49
Next >
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
December 19, 2022
From
Arcus Biosciences
Via
Business Wire
Could Gilead (GILD) Continue On The Bull Run?
December 17, 2022
Using the Wycoff trading method, we see that Gilead Sciences, Inc (GILD) will likely continue its bullish momentum.
Via
Talk Markets
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
Why Merck's $250 Million Investment In Moderna May Have Just Paid Off
December 13, 2022
Merck opted into Moderna's cancer vaccine. Now, the companies have Phase 2 data.
Via
Investor's Business Daily
Beat the Dow Jones With This Unstoppable Dividend Stock
December 12, 2022
Gilead Sciences is a 2022 winner that could stay hot in 2023.
Via
The Motley Fool
Why Is Arcellx (ACLX) Stock Up 25% Today?
December 09, 2022
ACLX stock is usually under the radar, but today it's in the spotlight as Arcellx reveals a team-up with a well-known biotech business.
Via
InvestorPlace
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 15 Years
December 08, 2022
Via
Benzinga
Gilead Sciences Again Named to Dow Jones Sustainability World Index
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Is Gilead Sciences a Buy?
December 08, 2022
This stock has got something to offer both dividend and growth investors.
Via
The Motley Fool
Expert Ratings for Gilead Sciences
December 01, 2022
Via
Benzinga
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
December 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
December 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
December 09, 2022
The company inked a deal worth $325 million and up to $3.9 billion in milestones.
Via
Investor's Business Daily
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
December 09, 2022
Via
Benzinga
2 Reasons This Stock Could Outperform in 2023
November 30, 2022
It would be a continuation of this year's showing.
Via
The Motley Fool
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
December 09, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
December 08, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
-Clinical Data Due Next Week at ASH-
Via
Benzinga
Is Gilead Sciences Stock Still a Buy After Soaring in 2022?
December 08, 2022
Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going.
Via
The Motley Fool
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
December 07, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
December 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Unusual Options Activity
December 02, 2022
Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
December 01, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
The Top Healthcare Stocks to Buy With $100
December 01, 2022
Triple-digit growth and innovation go hand-in-hand with these companies.
Via
The Motley Fool
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
These 3 Stocks Are Rallying While the Rest of the Market Plunges
November 30, 2022
Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds.
Via
The Motley Fool
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
November 29, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
48
49
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.